TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months

NCT ID: NCT04650828

Last Updated: 2021-01-12

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2022-12-30

Brief Summary

Studies have shown that the HBeAg seroconversion rate of HBeAg positive chronic hepatitis B with tenofovir for one year's treatment was 17.8% and the negative conversion rate of their HBeAg and HBV DNA were 20.0% and 97.6%. The HBeAg Seroconversion rate of these patients was lower.Clinically, most patients need to take tenofovir for a long time, which may cause serious complications such as renal function damage,with decreased therapy compliance and Increased cost of treatment.In the course of tenofovir treatment, it is common that HBV-DNA negative patients with HBeAg Being down poor or staying at a low positive level for a long time keep taking the medicine. Therefore, it is Significant to Increase the HBeAg seroconversion rate of tenofovir during the clinical treatment.

Telbivudine has a strong antiviral effect.Studies have shown that the HBeAg seroconversion rate of HBeAg positive CHB for one year was 25%, which was higher than other nucleosides, and it could also improve the damaged renal function to a certain extent.The HBeAg seroconversion rate of patients with poor response to tenofovir for 12 months could be still poor if for 24 months . Therefore, this study is to observe the efficacy of these patients combined with telbivudine.

Detailed Description

This is an open, multicenter, exploratory and real-world clinical study. It will be carried out in patients with poor response (HBV DNA > 2x103iu / ml) to tenofovir for 12 months. After one -week screening period, patients will be randomly assigned 1:1 to control and experimental groups. The control group takes tenofovir for 12 months while the experimental group takes tenofovir combined with telbivudinefor 12months .

Conditions

Chronic Hepatitis B

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Experimental:person with TDF+LDT

TDF combined with LDT for 12 months

TDF

Intervention Type: DRUG

TDF combined with telbivudine (LDT) for 12 months

Active comparator:person with TDF

TDF monotherapy was continued for 12 months

Tenofovir Disoproxil Fumarate 300 MG

Intervention Type: DRUG

TDF monotherapy was continued for 12 months

Interventions

TDF

TDF combined with telbivudine (LDT) for 12 months

Intervention Type: DRUG

Tenofovir Disoproxil Fumarate 300 MG

TDF monotherapy was continued for 12 months

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patients, aged 18 to 70 years, including 18 and 70 years old;

2. Patients with poor response to tenofovir for 12 months did not obtained HBeAg seroconversionPatients with poor response to tenofovir for 12 months who didn't obtain HBeAg seroconversion choosed to continue taking tenofovir or take tenofovir combined with Tbl for 12months;

3. Persons were willing to sign informed consent and comply with medication regimen and follow-up.

Exclusion Criteria

1. Co-infectious with hepatitis A, hepatitis C, hepatitis D, hepatitis E or HIV;

2. In the decompensated stage of liver cirrhosis, such as ascites, varicose bleeding or hepatic encephalopathy;

3. With malignant tumors (including hepatocellular carcinoma);

4. Concomitant with other liver diseases, such as alcoholic liver disease, autoimmune disease, or other systemic diseases involving the liver, such as hemochromatosis, Alpha-1 antitrypsin deficiency, or Wilson disease;

5. During the study period, chronic systemic steroid drugs are required or may be used under any medical conditions;

There are any other factors that the researcher thinks are not suitable for inclusion in the study, or that may affect the patient's participation or completion of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role: lead

Responsible Party

Chaoshuang Lin

Professor Lin

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Chaoshuang Lin

Guangzhou, , China

Site Status: RECRUITING

Countries

China

Facility Contacts

shufang pan

Role: primary

psf980730@163.com

13557981048

Other Identifiers

00000001

Identifier Type: -

Identifier Source: org_study_id